ACE and hydrops fetalis: Cardiologists tend to treat younger, predominantly male patients with more severe cardiac dysfunction, specifically HFrEF, accompanied by lower burden with comorbidities, adhering more closely to HF guidelines such as the use of angiotensin-converting enzyme (ACE)-inhibitors and beta-blockers, resulting in lower 9-month and 6-month cardiac-related mortality rates [42–44].